Skip to main content
. 2024 Sep 6;12(9):e6126. doi: 10.1097/GOX.0000000000006126

Table 3.

Outcomes at 2-Week Follow-up (n = 643)

Adverse events (n,%)
 Erythema 234 (36.4%)
 Swelling 159 (24.7%)
 Infection 0 (0%)
 Skin necrosis 3 (0.47%)
 Headache 3 (0.47%)
Patient satisfaction (0–10)
 Mean (SD) 7.4 (1.2)
Additional treatment? (n, %) 24 (3.7%)
Treatment volume, mL (range) (0.1–0.2 mL)